New drug cocktail aims to stop Chemo-Linked nausea before it starts

NCT ID NCT07692451

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests whether a combination of two drugs, fosrolapitant and palonosetron, can prevent nausea and vomiting caused by antibody-drug conjugates (ADCs) in cancer patients. Participants are adults with malignant tumors who have never received ADCs before and are about to start their first course. The trial compares the experimental drug combo against a standard treatment to see which better achieves a complete response (no vomiting and no need for rescue medication).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Fosrolapitant and Palonosetron for injection
What this could lead to
If successful, this could provide a new option to prevent nausea and vomiting in cancer patients receiving antibody-drug conjugates, improving treatment tolerability.
What could go wrong
This is a Phase 2 trial with a moderate number of participants, so results are preliminary. The drug may not prove more effective than existing treatments, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer Nausea

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.